Zana Brkic

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.

Journal: Frontiers in immunology
Published: April 01, 2026

Interferon-α in Sjögren's disease: cause or consequence?

Interferon-α in Sjögren's disease: cause or consequence?

Journal: The Lancet. Rheumatology
Published: March 11, 2026

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases.

Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases.

Journal: RMD open
Published: December 19, 2024

Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs.

Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs.

Journal: Orphanet journal of rare diseases
Published: December 19, 2024

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study.

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study.

Journal: BMC immunology
Published: October 18, 2024

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogenetics.

Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogenetics.

Journal: Frontiers in oncology
Published: December 23, 2022

Trained Immunity in Primary Sjögren's Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype.

Trained Immunity in Primary Sjögren's Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype.

Journal: Frontiers in immunology
Published: December 21, 2021

Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndrome.

Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)
Published: October 13, 2021

Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome.

Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome.

Journal: Rheumatology (Oxford, England)
Published: April 02, 2021

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department.

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department.

Journal: Journal of translational autoimmunity
Published: December 21, 2020

A 45-year-old woman with an anticholinergic toxidrome.

A 45-year-old woman with an anticholinergic toxidrome.

Journal: The Netherlands journal of medicine
Published: March 30, 2016

Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome.

Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome.

Journal: Annals of the rheumatic diseases
Published: March 21, 2016
Showing 1-12 of 20

Last Updated: 09/26/2026